Lecture Series: Perspectives on Step Therapy in Oncology

In August 2018, the Centers for Medicare & Medicaid Services (CMS) issued a memo announcing new guidance that allowed Medicare Advantage plans to implement step therapy for Part B drugs effective January 1, 2019. This regulatory shift reversed a 2012 CMS Health Plan Management System memo stating that "plans were precluded from imposing additional requirements for access to certain Part B drugs or services, such as step therapy requirements."

This lecture series (coming soon) explores the implications of potential implementation of step therapy in Medicare Advantage plans, which cover more than 20 million Medicare beneficiaries, on patient-centered cancer care delivery.

Our Supporter

This project is sponsored by Amgen.